REG - Cambridge Cognition - Board Appointment

Cambridge Cognition HoldingsAnnouncement

07/02/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250207:nRSG2388Wa&default-theme=true

RNS Number : 2388W  Cambridge Cognition Holdings PLC  07 February 2025

7(th) February 2025

Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

 

Board appointment

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group
specialising in digital products that advance brain health research and
treatment, is pleased to announce the appointment of Jonathan ("Jon") Kempster
as an independent Non-Executive Director of the Company, with immediate
effect.

Jon has more than 20 years' experience as a public company director and is
currently a Non-Executive Director of three AIM quoted companies: Norman
Broadbent plc, a leading Executive Search and Interim Management firm,
Synthetics plc, a leader in advanced security and surveillance systems, and
Pennant International Group plc, a systems support and training solutions
company.

Jon qualified as a chartered accountant with Price Waterhouse in 1990 and has
been CFO of a number of companies including FII Group plc, Linden Homes, Delta
plc, and Frasers Group. He has held several non-executive roles since 2019.

This appointment further strengthens the Board by adding additional investor
relations and financial expertise and, in taking the number of non-executive
directors to six, provides strengthened governance and ensuring robust
succession planning for possible future rotation of Board members.

Dr Steven Powell, Chairman of Cambridge Cognition, commented:

"On behalf of the Board, I am delighted to welcome Jon to Cambridge Cognition.
His broad experience and deep financial expertise will be a valuable addition
to the Company as we continue to build and grow the business."

Further information:

The following additional information is provided in accordance with Rule 17
and Schedule Two Paragraph (g) of the AIM Rules for Companies:

Jonathan (Jon) Kempster, aged 62, holds or has held the following
directorships in the last five years:

 Current directorships            Past directorships within the last five years
 Norman Broadbent plc             DX (Group) Limited
 Pennant International Group plc  Bonhill Group plc
 Synectics plc                    Independent Trustee Services Limited
 JVM AG                           Ted Baker Holdings Limited
 JVM Property AG                  Redcentric plc
 Rochester Associates Ltd         FireAngel Safety Technology Group plc
 Delta Pension Nominees Limited   FireAngel Safety Technology Limited
                                  Portcentric Solutions Limited
                                  Serinus Energy plc
                                  Prosped Solutions OU

 

Jonathan Kempster does not have any interest in any ordinary shares of the
Company.

Save for the information disclosed above, there is no other information in
relation to Jonathan Kempster that is required to be disclosed pursuant to
Rule 17 and Schedule Two paragraph (g) of the AІM Rules for Companies.

Enquiries:

 

 Cambridge Cognition Holdings plc                                Tel: 012 2381 0700
 Rob Baker, Chief Operating Officer and Joint Managing Director

 Panmure Liberum Limited (NOMAD and Joint Broker)                Tel: 020 7886 2968
 Will Goode / Freddy Crossley / Mark Rogers                      (Corporate Broking)
 Rupert Dearden                                                  (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                          Tel: 020 3903 7715
 David Poutney / James Serjeant

 Hudson Sandler (Financial PR and IR)                            Tel: 020 7796 4133
 Dan de Belder / Hattie Dreyfus / Harry Griffiths                cog@hudsonsandler.com

 

Notes to Editors

 

About Cambridge Cognition

Cambridge Cognition is a brain health software group specializing in digital
health products that advance brain health research and treatment. The company
offers four core products: CANTAB® assessments-providing scientifically
validated, highly sensitive, precise, and objective measures of cognitive
function correlated to neural networks; a flexible and proven eCOA platform
with an extensive library of instruments, enabling efficient study setup and
scalable data capture; rater training services that standardise assessment
delivery and scoring across clinical trials and quality assurance tools that
ensure data integrity by automatically detecting deviations in administration
and scoring, saving time and money. These products collectively improve
clinical trial outcomes, enable early patient identification, and enhance
global efficiency in healthcare and pharmaceuticals.

 

For further information, visit: www.cambridgecognition.com
(https://eur01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.cambridgecognition.com%2F&data=05%7C02%7Chgriffiths%40hudsonsandler.com%7Cc696c6a3150d40f91a9508dcfdd13b58%7Ca33bdb157e25438ab1fd5c523a8866f9%7C0%7C0%7C638664322305026349%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=vQVOIVxNQ8WYYOufDnSVKUH0oa7PLvXjnP0VT%2FzCfJc%3D&reserved=0)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAKZGGZKVVGKZM